Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM

Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Guiding transplant decisions in multiple myeloma with MRD

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Cabozantinib demonstrates significant improvement in PFS by BICR in advanced neuroendocrine tumours

Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients

Optimizing oncology: The future of treatment studies